Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 875 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 875 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $54.59, for a total transaction of $47,766.25. Following the completion of the transaction, the vice president now owns 31,698 shares in the company, valued at approximately $1,730,393.82. This trade represents a 2.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, June 16th, Patrick Lamy sold 2,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.14, for a total value of $108,280.00.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total value of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.31, for a total transaction of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total value of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Stock Down 1.3%

Shares of Akero Therapeutics stock traded down $0.70 during trading hours on Friday, reaching $54.20. The company's stock had a trading volume of 1,983,828 shares, compared to its average volume of 1,019,471. The company has a market capitalization of $4.32 billion, a P/E ratio of -27.79 and a beta of -0.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. Akero Therapeutics, Inc. has a one year low of $21.02 and a one year high of $58.40. The stock's fifty day simple moving average is $45.88 and its two-hundred day simple moving average is $41.10.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Bank of America raised their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Citigroup lowered their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $82.50.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently bought and sold shares of AKRO. RTW Investments LP increased its holdings in Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after buying an additional 940,388 shares during the last quarter. Deep Track Capital LP boosted its holdings in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after acquiring an additional 800,216 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Akero Therapeutics during the fourth quarter valued at about $18,059,000. SG Americas Securities LLC increased its holdings in Akero Therapeutics by 93.3% during the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after acquiring an additional 557,794 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Akero Therapeutics in the first quarter worth $21,333,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.